title: White cells 2: impact of understanding the molecular basis of haematological malignant disorders on clinical practice.
abstract: The molecular basis of many leukaemias is now known, allowing precise diagnosis. Treatment of chronic myeloid leukaemia is now possible by targeting of the BCR-ABL tyrosine kinase. The underlying molecular abnormalities in acute leukaemias allow the outlook for individual patients to be assessed at diagnosis and therapy tailored accordingly. Analysis of V(H) genes in B-cell malignant disorders allows these to be placed in the hierarchy of B-cell development and may provide prognostically valuable information.
authors.affiliation: Department of Medical Oncology, Princess Margaret Hospital, University of Toronto, Ontario, Canada. k.stewart@utoronto.ca
authors.forename: A K
authors.initials: AK
authors.lastname: Stewart
authors.forename: A C
authors.initials: AC
authors.lastname: Schuh
mesh_terms: D000208:Acute Disease; D002869:Chromosome Aberrations / Q000235:genetics*; D025063:Chromosome Disorders; D002908:Chronic Disease; D005820:Genetic Testing; D006689:Hodgkin Disease / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy; D006801:Humans; D007621:Karyotyping; D007945:Leukemia, Lymphoid / Q000097:blood / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy; D007951:Leukemia, Myeloid / Q000097:blood / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy; D008967:Molecular Biology; D009101:Multiple Myeloma / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy; D011379:Prognosis